このエントリーをはてなブックマークに追加
ID 32971
フルテキストURL
著者
Ito, Tatsuo Science of Functional Recovery and Reconstruction, Graduate School of Medicine and Dentistry, Okayama University
Ouchida, Mamoru Department of Molecular Genetics, Graduate School of Medicine and Dentistry, Okayama University
Morimoto, Yuki Science of Functional Recovery and Reconstruction, Graduate School of Medicine and Dentistry, Okayama University
Yoshida, Aki Science of Functional Recovery and Reconstruction, Graduate School of Medicine and Dentistry, Okayama University
Jitsumori, Yoshimi Department of Molecular Genetics, Graduate School of Medicine and Dentistry, Okayama University
Ozaki, Toshifumi Science of Functional Recovery and Reconstruction, Graduate School of Medicine and Dentistry, Okayama University
Sonobe, Hiroshi Department of Laboratory Medicine and Pathology, National Fukuyama Hospital
Inoue, Hajime Science of Functional Recovery and Reconstruction, Graduate School of Medicine and Dentistry, Okayama University
Shimizu, Kenji Department of Molecular Genetics, Graduate School of Medicine and Dentistry, Okayama University
抄録
About 97% of synovial sarcomas harbor the SYT-SSX fusion gene by chromosomal translocation. We found that the histone deacetylase (HDAC) inhibitor FK228 significantly suppressed the growth of synovial sarcoma cells as compared with that of osteosarcoma. The 50% growth inhibition IC50 value we obtained for FK228 was 0.02-0.2 nM, and it indicates that its suppression effect on synovial sarcoma cells is the highest of any of the HDAC inhibitors yet reported. It was not likely that the growth suppression of FK228 depends on the doubling time of these cells. Introduction of SYT-SSX cDNA into HEK293 cells enhanced the sensitivity of the cells for FK228. Immunostaining of the FK228-treated cells using an anti-acetyl-histone H3 antibody showed that FK228 inhibits deacetylation of histone. In a mice assay, the growth of synovial sarcoma cells was markedly inhibited by FK228 treatment, and the invasion of tumors into surrounding tissues was suppressed. These results suggest that FK228 may be useful in developing therapeutic strategies to treat synovial sarcoma.
キーワード
histone deacetylase inhibitor
synovial sarcoma
growth inhibition
in vivo
備考
Digital Object Identifer:10.1016/j.canlet.2004.10.030
Published with permission from the copyright holder. This is the author's copy, as published in Cancer Letters, June 2005, Volume 224, Issue 2, Pages 311-319.
Publisher URL:http://dx.doi.org/10.1016/j.canlet.2004.10.030
Direct access to Thomson Web of Science record
Copyright © 2004 Elsevier Ireland Ltd. All rights reserved.
発行日
2005-06-28
出版物タイトル
Cancer Letters
224巻
2号
出版者
Elsevier Ireland Ltd.
開始ページ
311
終了ページ
319
ISSN
0304-3835
NCID
AA00598513
資料タイプ
学術雑誌論文
言語
English
著作権者
Elsevier Ireland Ltd.
論文のバージョン
author
査読
有り
DOI
PubMed ID
Web of Sience KeyUT
Submission Path
biology_general/28